Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

116 trials with published results (24%)

Research Maturity

287 completed trials (60% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

4.6%

22 terminated out of 479 trials

Success Rate

92.9%

+6.4% vs benchmark

Late-Stage Pipeline

28%

136 trials in Phase 3/4

Results Transparency

40%

116 of 287 completed with results

Key Signals

116 with results93% success22 terminated

Data Visualizations

Phase Distribution

381Total
Not Applicable (66)
Early P 1 (2)
P 1 (72)
P 2 (105)
P 3 (67)
P 4 (69)

Trial Status

Completed287
Unknown77
Recruiting33
Active Not Recruiting23
Terminated22
Withdrawn21

Trial Success Rate

92.9%

Benchmark: 86.5%

Based on 287 completed trials

Clinical Trials (479)

Showing 20 of 20 trials
NCT07449923Phase 3RecruitingPrimary

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936Phase 3RecruitingPrimary

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07567898Not ApplicableNot Yet RecruitingPrimary

Effectiveness of Multidisciplinary Protocolised Interventions on IVT Non-adherence Rates

NCT05066997Phase 2CompletedPrimary

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)

NCT06172257Phase 3CompletedPrimary

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)

NCT05978622Active Not RecruitingPrimary

Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

NCT07489131Phase 3RecruitingPrimary

Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema

NCT07553429Phase 1Not Yet RecruitingPrimary

A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated

NCT06850922Phase 1Active Not RecruitingPrimary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

NCT07425522Phase 1RecruitingPrimary

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

NCT05112861Phase 3Active Not Recruiting

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

NCT06847854Phase 1Active Not RecruitingPrimary

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

NCT05610319Phase 4Active Not RecruitingPrimary

Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

NCT05959304Phase 4CompletedPrimary

Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.

NCT06680817Recruiting

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

NCT06422507Phase 3CompletedPrimary

A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

NCT07501052Phase 2Not Yet Recruiting

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

NCT07481500Not ApplicableNot Yet Recruiting

Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety

NCT05476926Active Not Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05217680Phase 3CompletedPrimary

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema

Scroll to load more

Research Network

Activity Timeline